MIRM Maintains Outperform Rating -- Price Target Raised to $146
Evercore ISI Group maintained an Outperform rating for Mirum Pharmaceuticals (MIRM) and raised its price target from $135.00 to $146.00. The company's GF Value is $82.70, suggesting it is 1.7% undervalued. Mirum has a GF Score of 51/100, with strong momentum but weak profitability. Insiders have sold $10.78 million in shares over the last three months.
How this was made
The 30-second read
Why it matters
The rating lift may prompt short‑term buying, but long‑term performance hinges on profitability and pipeline progress.
Market read
Analyst target raise is a fresh catalyst that could move MIRM modestly; broader market impact is limited.
What to watch
The company's unprofitability and high P/S ratio may limit upside; the upgrade may be speculative.
Background
Mirum Pharmaceuticals is a commercial‑stage biotech focused on rare liver diseases; its lead product Livmarli is gaining market traction.
Ticker impact
Evercore ISI Group maintained an Outperform rating and raised Mirum Pharmaceuticals' price target to $146, up from $135.
likely upward pressure as investors price in the higher target
The rating change is fresh news and the new target is materially above the current price, which can attract buying interest.
Market effects
May boost sentiment toward biotech stocks with similar rare‑disease pipelines.
Limited to U.S. markets where MIRM trades.
Minor; primarily affects investors tracking Nasdaq biotech listings.
Counterpoint
Insider selling of over $10 M could signal concerns despite the rating upgrade.
Key entities
- AnalystEvercore ISI Group
Equity research firm that issued the rating update.
- CompanyMirum Pharmaceuticals
Biopharma developing therapies for orphan liver diseases.
